Lyell Immunopharma, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Lyell Immunopharma, Inc. (LYEL) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$3.33 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-06
- Lyell Immunopharma, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$3.23M.
- Lyell Immunopharma, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$90.00K.
- Lyell Immunopharma, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $2.39M.
- Lyell Immunopharma, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$420.00K, a 126.01% decline year-over-year.
- Lyell Immunopharma, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$2.82M.
- Lyell Immunopharma, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$1.77M.
- Lyell Immunopharma, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$3.13M, a 258.79% decline from fiscal 2022.
- Lyell Immunopharma, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $1.97M, a 71.83% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$3.33M 10-Q · filed 2026-08-06 | -$932.00K derived: sum of 3 quarters · filed 2026-08-06 | -$1.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$90.00K 10-Q · filed 2026-05-06 | $2.30M derived: sum of 2 quarters · filed 2026-05-06 | $1.88M derived: sum of 3 quarters · filed 2026-05-06 | -$913.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.97M derived: sum of 2 quarters · filed 2026-03-12 | -$823.00K derived: sum of 3 quarters · filed 2026-08-06 | -$2.82M 10-K · filed 2026-03-12 |
| 2025-09-30 | -$420.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$3.22M derived: sum of 2 quarters · filed 2026-08-06 | -$5.22M 10-Q · filed 2025-11-12 | -$8.85M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$2.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$4.80M 10-Q · filed 2026-08-06 | -$8.43M derived: sum of 3 quarters · filed 2026-08-06 | -$6.82M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$2.00M 10-Q · filed 2026-05-06 | -$5.64M derived: sum of 2 quarters · filed 2026-05-06 | -$4.02M derived: sum of 3 quarters · filed 2026-05-06 | -$3.18M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$3.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$2.02M derived: sum of 2 quarters · filed 2026-03-12 | -$1.18M derived: sum of 3 quarters · filed 2026-03-12 | -$1.77M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $2.46M derived: sum of 2 quarters · filed 2025-11-12 | $1.86M 10-Q · filed 2025-11-12 | -$1.29M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | $841.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $246.00K 10-Q · filed 2025-08-12 | -$2.90M derived: sum of 3 quarters · filed 2026-03-12 | -$2.24M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | -$595.00K 10-Q · filed 2025-05-13 | -$3.74M derived: sum of 2 quarters · filed 2026-03-12 | -$3.08M derived: sum of 3 quarters · filed 2026-03-12 | -$4.13M derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | -$3.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$2.48M derived: sum of 2 quarters · filed 2026-03-12 | -$3.53M derived: sum of 3 quarters · filed 2026-03-12 | -$3.13M 10-K · filed 2026-03-12 |
| 2023-09-30 | $664.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$385.00K derived: sum of 2 quarters · filed 2024-11-07 | $23.00K 10-Q · filed 2024-11-07 | $1.32M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-06-30 | -$1.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$641.00K 10-Q · filed 2024-08-07 | $655.00K derived: sum of 3 quarters · filed 2025-03-11 | $1.34M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-03-31 | $408.00K 10-Q · filed 2024-05-06 | $1.70M derived: sum of 2 quarters · filed 2025-03-11 | $2.38M derived: sum of 3 quarters · filed 2025-03-11 | $1.98M derived: sum of 4 quarters · filed 2025-03-11 |
| 2022-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $1.98M derived: sum of 2 quarters · filed 2025-03-11 | $1.57M derived: sum of 3 quarters · filed 2025-03-11 | $1.97M 10-K · filed 2025-03-11 |
| 2022-09-30 | $681.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $275.00K derived: sum of 2 quarters · filed 2023-11-07 | $672.00K 10-Q · filed 2023-11-07 | $848.00K derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$406.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$9.00K 10-Q · filed 2023-08-08 | $167.00K derived: sum of 3 quarters · filed 2024-02-28 | $2.04M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $397.00K 10-Q · filed 2023-05-04 | $573.00K derived: sum of 2 quarters · filed 2024-02-28 | $2.44M derived: sum of 3 quarters · filed 2024-02-28 | $7.04M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $176.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $2.04M derived: sum of 2 quarters · filed 2024-02-28 | $6.64M derived: sum of 3 quarters · filed 2024-02-28 | $6.99M 10-K · filed 2024-02-28 |
| 2021-09-30 | $1.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $6.47M derived: sum of 2 quarters · filed 2022-11-08 | $6.81M 10-Q · filed 2022-11-08 | $7.60M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $4.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $4.94M 10-Q · filed 2022-08-04 | $5.73M derived: sum of 3 quarters · filed 2023-02-28 | $4.85M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $342.00K 10-Q · filed 2022-05-10 | $1.13M derived: sum of 2 quarters · filed 2023-02-28 | $247.00K derived: sum of 3 quarters · filed 2023-02-28 | |
| 2020-12-31 | $792.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$95.00K derived: sum of 2 quarters · filed 2023-02-28 | $1.39M 10-K · filed 2023-02-28 | |
| 2020-09-30 | -$887.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $596.00K 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $1.48M 10-Q · filed 2021-08-12 | |||
| 2019-12-31 | $5.77M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |